These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
669 related articles for article (PubMed ID: 25529996)
21. [The Brazilian market for monoclonal antibodies used in cancer treatment]. Vidal TJ; Figueiredo TA; Pepe VLE Cad Saude Publica; 2018 Nov; 34(12):e00010918. PubMed ID: 30517310 [TBL] [Abstract][Full Text] [Related]
22. mAbs: a business perspective. Scolnik PA MAbs; 2009; 1(2):179-84. PubMed ID: 20061824 [TBL] [Abstract][Full Text] [Related]
23. Lymphoma treatment approved. AIDS Patient Care STDS; 1998 Mar; 12(3):231. PubMed ID: 11361944 [No Abstract] [Full Text] [Related]
24. Therapeutic monoclonal antibodies: trends in development and approval in the US. Reichert JM Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031 [TBL] [Abstract][Full Text] [Related]
26. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related]
27. Can next-generation antibodies offset biosimilar competition? Mullard A Nat Rev Drug Discov; 2012 Jun; 11(6):426-8. PubMed ID: 22653202 [No Abstract] [Full Text] [Related]
28. GlaxoSmithKline cancer drug threatens Herceptin market. Waltz E Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273 [No Abstract] [Full Text] [Related]
29. Thumbs up for Avastin. Spalding BJ Nat Biotechnol; 2008 Apr; 26(4):365. PubMed ID: 18392003 [No Abstract] [Full Text] [Related]
30. Just mad about mAbs. Jacobs T Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498 [No Abstract] [Full Text] [Related]
31. [Diagnostic kits in parasitology: which controls?]. Rossi P Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705 [TBL] [Abstract][Full Text] [Related]
32. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]. Tobinai K Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743 [TBL] [Abstract][Full Text] [Related]
33. Fast track to MS drug. Sheridan C Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635 [No Abstract] [Full Text] [Related]
36. Antibodies to watch in 2014: mid-year update. Reichert JM MAbs; 2014; 6(4):799-802. PubMed ID: 24846335 [TBL] [Abstract][Full Text] [Related]
37. Canadian and US drug approval times and safety considerations. Rawson NS; Kaitin KI Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031 [TBL] [Abstract][Full Text] [Related]
38. The United States pork niche market phenomenon. Honeyman MS; Pirog RS; Huber GH; Lammers PJ; Hermann JR J Anim Sci; 2006 Aug; 84(8):2269-75. PubMed ID: 16864889 [TBL] [Abstract][Full Text] [Related]
39. FDA. Once on 'fast track,' avastin now derailed. Couzin-Frankel J; Ogale Y Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712 [No Abstract] [Full Text] [Related]
40. [The story of biosimilars--chance or threat?]. Woroń J; Kocić I Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]